What 7 Analyst Ratings Have To Say About BioCryst Pharma
Portfolio Pulse from Benzinga Insights
In the last quarter, BioCryst Pharma (NASDAQ:BCRX) received 7 analyst ratings, with 4 being bullish, 2 somewhat bullish, and 1 indifferent. The company's average 12-month price target is $13.14, with a high of $30.00 and a low of $9.00. This average price target has increased by 27.2% over the past month.
September 25, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharma received mostly bullish analyst ratings in the last quarter, which could positively impact its stock price. The average 12-month price target has also increased significantly.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In the case of BioCryst Pharma, the majority of the ratings are bullish, which is a positive signal for the company. Additionally, the significant increase in the average 12-month price target suggests that analysts are optimistic about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100